Abstract
Ceftazidime (CAZ, SN401) was evaluated for its clinical efficacy in 28 patients, namely, 10 with pneumonia, 3 with acute cystitis, 5 with chronic cystitis, 6 with acute pyelonephritis, 2 with chronic pyelonephritis and 2 with acute cholecystitis.
The clinical response obtained was excellent in 9 patients, good in 15, fair in 1 and poor in 3. Out of 24 strains assumed to be causative organisms, 21 strains of organisms were eradicated and 1 decreased in number and the others were replaced.
The only side effect noted was exanthema in 1 patient. Laboratory abnormalities were mild erythropenia and slight elevation of GPT in 1 case each. From the above results, the drug was considered to be useful in respiratory tract infections and urinary tract infections.
